Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.
2.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

4.

Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.

Laneuville P, Barnett MJ, Bélanger R, Couban S, Forrest DL, Roy DC, Lipton JH.

Curr Oncol. 2006 Dec;13(6):201-21.

5.

Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

Affer M, Dao S, Liu C, Olshen AB, Mo Q, Viale A, Lambek CL, Marr TG, Clarkson BD.

J Oncol. 2011;2011:798592. doi: 10.1155/2011/798592. Epub 2011 Feb 23.

6.

Epigenetic gene regulation in stem cells and correlation to cancer.

Mathews LA, Crea F, Farrar WL.

Differentiation. 2009 Jul;78(1):1-17. doi: 10.1016/j.diff.2009.04.002. Epub 2009 May 14. Review.

7.

Cancer driver mutations in protein kinase genes.

Torkamani A, Verkhivker G, Schork NJ.

Cancer Lett. 2009 Aug 28;281(2):117-27. doi: 10.1016/j.canlet.2008.11.008. Epub 2008 Dec 10. Review.

8.

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW.

Blood. 2008 Sep 1;112(5):1960-70. doi: 10.1182/blood-2007-09-113860. Epub 2008 Jun 17.

9.

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G.

J Clin Invest. 2007 Dec;117(12):4044-54. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

10.

Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Williams RT, den Besten W, Sherr CJ.

Genes Dev. 2007 Sep 15;21(18):2283-7. Epub 2007 Aug 30.

11.

Treatment for chronic myelogenous leukemia: the long road to imatinib.

Hunter T.

J Clin Invest. 2007 Aug;117(8):2036-43. Review.

12.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

Items per page

Supplemental Content

Write to the Help Desk